Quarterly Activities and Cash Flow Report – Q1 FY24

Report Highlights:

• Amplia Therapeutics Ltd. (ASX: ATX) is pleased to announce the successful completion of the first patient cohort in its Phase 2a clinical trial of narmafotinib targeting pancreatic cancer, reporting six confirmed partial responses out of 26 patients. As a result, recruitment has resumed to enroll an additional 24 patients, aiming to reach a total of 50 participants by the end of Q1 2025.
• The U.S. FDA granted Fast Track Designation to narmafotinib, recognizing its potential as a treatment for advanced pancreatic cancer. This designation will facilitate an accelerated development process, providing Amplia with enhanced opportunities to interact with the FDA and opening the potential for Priority Review or Accelerated Approval, which could bring the drug to patients sooner.
• Amplia reported a closing cash balance of AUD 4.6M (USD 3.02M) for the quarter ending September 30, 2024, and achieved net cash inflows of AUD 1.3M (USD 855K) during the period. These inflows were primarily bolstered by an AUD 3.2M (USD 2.1M) R&D Tax Incentive refund, which enabled the company to fully repay its AUD 1.47M (USD 967K) R&D funding loan, strengthening its financial position for continued trial activities.